Pills masthead

News Releases

Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015

2014201320122011201020092008200720062004

2017 Archives

Jun 16, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Amantadine...

More
May 26, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that its chief executive officer, Arthur Bedrosian, received a top rating in a report by Owler, the world's largest community-based business...

More
May 16, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Levocetirizine...

More
May 9, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily paid down the remaining principal balance of $25 million against its existing revolving credit facility. "Since...

More
May 2, 2017

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 third quarter ended March 31, 2017. "Net sales in our fiscal 2017 third quarter increased compared with the...

More
Apr 28, 2017

Lannett Company, Inc. (NYSE: LCI) today announced its participation at three upcoming investor conferences. These include the: Deutsche Bank 42nd Annual Health Care Conference at 8 a.m. ET, on...

More
Apr 25, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 third quarter on Tuesday, May 2, 2017, after the market closes. Lannett management will...

More
Mar 30, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $25 million payment against its existing revolving credit facility. "This $25 million payment, combined with...

More
Mar 27, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that its former chairman and chief executive officer William (Bill) Farber, R. Ph., has passed away from natural causes. Mr. Farber served as the...

More
Feb 27, 2017

Lannett Company, Inc. (NYSE: LCI) today announced its participation at four upcoming investor conferences. These include: Deutsche Bank's Pharma One-on-One Day, to be held at the JW Marriott...

More
Feb 23, 2017
--Kristin Arnold, Ph.D., Joins as Vice President of Research and Development--

Lannett Company, Inc. (NYSE: LCI) today announced that Kristin A. Arnold, Ph.D., has joined the company as vice president of research and development, effective February 27, 2017. "As head of...

More
Feb 22, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it was notified by U.S. Food and Drug Administration (FDA) late yesterday afternoon that FDA suspended indefinitely the deadline for the...

More
Feb 7, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the extraction of the core software supporting the operations of Kremers Urban Pharmaceuticals, Inc. (KU) from UCB Pharma....

More
Feb 1, 2017
--Net Sales Increased 35% to Approximately $171 Million; Company Continues to Expect Strong Fiscal Year--

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 second quarter ended December 31, 2016. The company completed the acquisition of Kremers Urban...

More
Jan 25, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2017 second quarter on Wednesday, February 1, 2017, after the market closes. Lannett...

More
Jan 23, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company voluntarily made a $75 million payment against its existing revolving credit facility. "This payment is consistent with our...

More
Jan 3, 2017
--Company May Be Eligible for 180 Days of Generic Drug Marketing Exclusivity--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval last week from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lopinavir...

More
 
Price Data
NYSELCI